Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study


Creative Commons License

Kalincik T., Brown J. W. L. , Robertson N., Willis M., Scolding N., Rice C. M. , ...Daha Fazla

LANCET NEUROLOGY, cilt.16, ss.271-281, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 16 Konu: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/s1474-4422(17)30007-8
  • Dergi Adı: LANCET NEUROLOGY
  • Sayfa Sayıları: ss.271-281

Özet

Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown. We compared the effectiveness of alemtuzumab with natalizumab, fingolimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to 5 years.